Understanding Soft Tissue Sarcoma: A Guide for Newly Diagnosed Dog Owners

Soft tissue sarcoma (STS) is a group of cancers that arise from the connective tissues of the body: muscle, fat, fibrous tissue, blood vessel walls, and nerve sheaths. In dogs, most of these tumors grow as a firm lump under the skin, invade locally along tissue planes, and spread to distant organs at a relatively low rate.

For the majority of dogs, this is a treatable diagnosis. Most canine soft tissue sarcomas are low or intermediate grade, and when they are removed surgically with adequate margins, many dogs are effectively cured. Higher-grade tumors are more serious and require a more aggressive plan, but they are the minority of cases. The single most important factor in your dog's outcome is getting the first surgery right,which means an accurate diagnosis, appropriate imaging, and a surgeon who plans wide margins from the start.

If you have just received this diagnosis, take a breath. You almost certainly have time to ask questions, get a second opinion, and make a considered plan.

Key Points

• This is not one disease. STS is an umbrella term covering fibrosarcoma, perivascular wall tumor, peripheral nerve sheath tumor, myxosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, among others. They are grouped together because they behave similarly.
• Common, and usually not the worst news. STS accounts for roughly 8–15% of skin and under-the-skin tumors in dogs, most often in middle-aged to senior, medium-to-large-breed dogs.
• Locally invasive, less often metastatic. These tumors send microscopic "tentacles" into surrounding tissue, which is why they recur if incompletely removed. Distant spread is uncommon in low-grade tumors and substantially more likely in high-grade ones.
• Grade drives everything. Grade I and II tumors carry a good prognosis with complete excision. Grade III tumors need a more aggressive approach and closer monitoring.
• A needle aspirate often isn't enough. Connective tissue cells don't shed well, so cytology is frequently inconclusive. A biopsy is usually needed for a definitive diagnosis and grade.
• Don't let anyone "pop it out." Shelling the mass out of its false capsule leaves cancer cells behind and makes the necessary second surgery larger and harder.
• Radiation is a strong backup. When margins come back incomplete, follow-up radiation therapy gives excellent long-term local control for many dogs.
• Chemotherapy has a limited, specific role. It's generally reserved for high-grade tumors or documented spread — not routine for most dogs.

Detailed Explanation

What Is Soft Tissue Sarcoma?

Your dog's body is held together by connective tissue: the fibrous sheets that wrap muscles, the fat under the skin, the walls of blood vessels, the coverings of nerves. Soft tissue sarcomas are malignant tumors that arise from these tissues.

Pathologists can subdivide them into named types, and you may see one of those names on your dog's report. In practical terms, the subtype matters far less than two other things: the grade and whether it can be completely removed. Veterinary oncologists group these tumors together precisely because their clinical behavior is so similar regardless of the specific cell of origin.

It's worth knowing that the word "sarcoma" carries more alarm than the biology often warrants. Specialists have actively debated the terminology, because most of these tumors in dogs are low grade, behave in a locally invasive but indolent way, and are curable with good local control.

How grading works. Pathologists assign a grade by scoring three features: how well-differentiated the cells are, how many cells are actively dividing (the mitotic count), and how much of the tumor is dead tissue (necrosis). The scores are added to produce Grade I (low), Grade II (intermediate), or Grade III (high).

What grade means for risk of spread. Reported metastasis rates vary between studies, but the pattern is consistent: spread is rare in Grade I tumors, uncommon in Grade II (published ranges span roughly 0–20%), and substantially more likely in Grade III (published ranges span roughly 22–50%). When these tumors do spread, they travel through the bloodstream, most often to the lungs. Lymph node involvement is unusual — one series found it in fewer than 2% of dogs.

Where they show up. Up to 60% of canine soft tissue sarcomas occur on the limbs, about 35% on the trunk, and around 5% on the head or neck. Limb tumors can be the hardest to remove widely, simply because there isn't much spare tissue on a leg.

Common Symptoms to Watch For

The classic presentation is quiet, which is part of why these tumors are often larger than expected by the time they're found.

• A firm, slowly enlarging lump under the skin or within a muscle. It may feel fixed to deeper tissue rather than sliding freely.
• No pain at all, in most cases. Uncomplicated soft tissue sarcomas are typically painless. Owners often report the dog seemed completely normal.
• Pain or discomfort if the mass ulcerates through the skin, or if it sits near a joint and interferes with movement.
• Lameness or a changed gait when the tumor involves a limb, particularly near a joint or a large muscle group.
• Location-specific signs for tumors in less visible places: straining to defecate, vomiting, or difficulty urinating with abdominal masses; noisy breathing, difficulty swallowing, or regurgitation with masses in the neck or chest.

A slow-growing, painless lump is easy to dismiss. The practical rule most oncologists recommend: any mass that has been present for more than a month, or is larger than a pea, deserves to be sampled rather than watched.

Diagnostic Steps

Understanding the sequence ahead of time makes the vet visits far less disorienting.

1. Fine-needle aspirate (FNA). A small needle collects cells for a pathologist to review. It's quick, inexpensive, and usually done without sedation. It's a reasonable first step — but be prepared for it to be inconclusive. Mesenchymal cells exfoliate poorly, and in one study of dogs with STS, aspirate results were inconclusive or inconsistent in 38% of cases.

2. Biopsy. For a definitive diagnosis and a grade, a tissue sample is needed. This is typically an incisional biopsy (a wedge or needle-core sample), not removal of the whole mass. Two things to understand here:

• The biopsy tract itself becomes contaminated with tumor cells and must be removed with the tumor at the definitive surgery. Your surgeon needs to know where it is — ideally, the same specialist plans both.
• The grade from a small biopsy sample doesn't always match the grade from the whole tumor after removal. Studies report discordance in roughly 12–41% of cases, with underestimation more common than overestimation. This means final prognosis conversations should wait until the whole mass has been examined.

3. Imaging for surgical planning. CT or MRI shows how deeply the tumor invades and what structures it touches. This is what allows a surgeon to plan realistically rather than discover the extent mid-procedure. MRI is preferred for tumors involving nerve plexuses.

4. Staging for spread. Chest radiographs (typically three views) or a chest CT check the lungs. Bloodwork and urinalysis assess overall health and anesthetic fitness. Lymph nodes are generally only sampled if they're enlarged, given how rarely these tumors travel that route.

A note on what to avoid: an "excisional biopsy" — removing the whole lump without knowing what it is — is specifically discouraged for suspected soft tissue sarcoma. It disrupts tissue planes, leaves microscopic disease, and makes the necessary second surgery considerably larger. Multiple attempts at resection are associated with worse outcomes.

Treatment Options

Surgery is the mainstay. The goal is en bloc resection: removing the tumor together with a cuff of normal-looking tissue on all sides, in one piece, without ever cutting into the mass itself. Soft tissue sarcomas develop a pseudocapsule — a compressed rim of tissue that looks like a clean boundary but is often infiltrated by tumor cells. This is why "shelling out" the mass reliably fails.

Current consensus recommendations scale the margins to grade:

Where a tumor is confined to a single muscle or muscle group, some surgeons remove the entire compartment from origin to insertion, which uses the body's own anatomical barriers to contain the disease.

Why margins matter so much. A study of nearly 100 dogs found the three-year local recurrence rate was 7% when margins were tumor-free, 23% when they were clean but close, and 42% when tumor cells reached the cut edge. Complete excision is the difference between a likely cure and a likely recurrence.

For limb tumors where wide margins aren't achievable, amputation is sometimes recommended. It is a hard conversation, and it is worth knowing that most dogs adapt to three legs remarkably well.

Radiation therapy. Radiation is the standard follow-up when margins come back incomplete or narrow, and it targets the microscopic disease surgery couldn't reach. Treatment usually starts two to four weeks after surgery, once the incision has healed, and involves a course of 10–20 sessions delivered three to five times a week. Each session requires brief general anesthesia because the dog must lie perfectly still.

Adjuvant radiation improves local control in roughly 70–80% of cases, with one- and three-year local control rates around 81% and 73%. Side effects during treatment — redness, skin flaking, hair loss in the treated area — typically appear in the second or third week and resolve on their own. Long-term scarring of tissue is uncommon at standard doses.

Radiation can also be used before surgery to shrink a tumor and make removal feasible, or palliatively in a small number of larger doses to relieve pain when a cure isn't the goal. Palliative protocols produce clinical improvement in roughly 50–80% of patients, typically lasting four to eleven months.

Chemotherapy. This is where expectations need calibrating. Conventional chemotherapy has not demonstrated a consistent survival benefit for canine soft tissue sarcoma. Doxorubicin is the most effective single agent, with response rates around 23%. It's generally reserved for Grade III tumors or documented metastatic disease — not offered routinely.

Metronomic chemotherapy — continuous low-dose oral medication rather than periodic high doses — has more encouraging data for one specific situation. In dogs with incompletely removed tumors, low-dose cyclophosphamide combined with piroxicam significantly delayed recurrence compared with surgery alone. It's a reasonable option when radiation isn't accessible or affordable, though it isn't a replacement for it. Side effects are usually mild, but sterile hemorrhagic cystitis (bladder inflammation) is the main concern to monitor.

Electrochemotherapy is an emerging option in some practices, used alongside surgery when radiation isn't available. Current consensus does not support it as a standalone treatment or as a substitute for radiation at deep margins.

Supportive care runs alongside all of this: pain control, wound management after what is often an extensive surgery, nutritional support, and honest attention to how your dog is actually doing day to day.

When to Contact Your Veterinarian

Call your veterinary team promptly if you notice:

• Any new lump, or an existing lump that changes in size, firmness, or attachment to underlying tissue
• A previously painless mass that becomes painful, warm, or breaks open through the skin
• New or worsening lameness, reluctance to use a limb, or difficulty rising
• Swelling, discharge, heat, or gaping at a surgical incision
• A firm swelling at or near a previous surgical site — this may indicate recurrence and is easier to address early
• Coughing, increased respiratory effort, or exercise intolerance, which can indicate spread to the lungs
• Straining to urinate or defecate, persistent vomiting, or regurgitation, particularly with internal masses
• Loss of appetite, lethargy, or weight loss that persists more than a day or two

Seek emergency care immediately for labored breathing, collapse, uncontrolled bleeding, or signs of severe pain such as crying out, panting at rest, or refusing to be touched.

Questions to Ask Your Veterinarian

Bring these written down. Diagnosis appointments are overwhelming, and it's normal to forget everything the moment you walk in.

About the diagnosis

1. What subtype and grade is my dog's tumor, and how confident are we in that grade at this stage?
2. Was the grade determined from a small biopsy or the whole mass? Could it change after surgery?
3. What is the mitotic count on the report, and what does that mean for my dog specifically?

About staging and planning 4. Do we have chest imaging, and did it show anything concerning? 5. Would a CT or MRI change the surgical plan? Is it worth the cost in our situation? 6. Where exactly is the biopsy tract, and will it be removed with the tumor?

About surgery 7. What margins are you planning, and are they achievable in this location? 8. Should this be done by a board-certified surgeon rather than in general practice? 9. What does reconstruction and recovery look like? How long until my dog is comfortable? 10. What happens if the margins come back incomplete — what's plan B, and what does it cost?

About the bigger picture 11. Is my dog a candidate for radiation, and where is the nearest facility? 12. Does chemotherapy have a role here, or would we be treating for the sake of treating? 13. What is a realistic range of outcomes for a dog like mine — and what does "median survival" actually mean for an individual patient? 14. What is the monitoring schedule after treatment, and what am I watching for at home? 15. If we choose not to pursue aggressive treatment, what does good palliative care look like?

Empowering Your Journey

A cancer diagnosis strips away your sense of control. Rebuilding it doesn't require becoming an expert overnight — it requires a system. The Dog Cancer Roadmap is built around five moves that consistently make a difference:

1. Get the pathology report in your hands. Not a summary — the actual document. It contains the subtype, grade, mitotic count, and margin status. These four data points determine nearly every decision ahead. Ask for a copy and keep it.

2. Decide about specialist referral before the first surgery, not after. This is the highest-leverage decision you will make. A first surgery planned with adequate margins is often curative. A first surgery that leaves disease behind commits you to a larger second surgery, radiation, or both. If a referral is financially or logistically impossible, say so plainly — your veterinarian can plan differently when they know the constraints.

3. Build a written timeline. Date of first noticing the lump. Date of aspirate. Date of biopsy and result. Date of surgery. Date margins came back. Recheck dates. Six months from now, when you're trying to recall whether a swelling is new, this document will be worth more than your memory.

4. Ask about cost early and directly. Estimates for surgery, radiation, and follow-up vary enormously by region and facility. Veterinary teams are used to this conversation and would far rather have it upfront than watch a family run out of resources midway through a plan. Ask about payment plans, pet insurance coverage, and whether a clinical trial might be an option.

5. Track quality of life on paper, not in your head. Appetite, mobility, interest in favorite activities, sleep, and comfort — scored weekly. Day-to-day changes are invisible when you live with a dog; a written record makes trends obvious and takes some of the weight off decisions you may face later.

Conclusion

Here is what's easy to lose sight of in the first week: the prognosis for most dogs with soft tissue sarcoma is genuinely good. Most of these tumors are low or intermediate grade. Most are locally invasive rather than aggressively metastatic. When complete surgical removal is achieved, many dogs live out normal lifespans and die of something else entirely.

Even when the picture is more complicated — an incomplete margin, a high-grade tumor, a location that makes wide removal impossible — there are real options. Radiation offers years of local control for many dogs. Palliative approaches can preserve comfort and joy for meaningful stretches of time. And the goal was never a number on a chart; it was a dog who is comfortable, engaged, and still recognizably himself.

You don't have to have all the answers today. You need to understand the grade, protect the chance of a good first surgery, and keep asking questions until the plan makes sense to you. Your dog has no idea he's sick. He knows you're there.

Sources

Bray, J. P. (2016). Soft tissue sarcoma in the dog – Part 1: A current review. Journal of Small Animal Practice, 57(10), 510–519. https://doi.org/10.1111/jsap.12556

Bray, J. P. (2017). Soft tissue sarcoma in the dog – Part 2: Surgical margins, controversies and a comparative review. Journal of Small Animal Practice, 58(2), 63–72. https://doi.org/10.1111/jsap.12629

Bray, J. P., Polton, G. A., McSporran, K. D., Bridges, J., & Whitbread, T. M. (2014). Canine soft tissue sarcoma managed in first opinion practice: Outcome in 350 cases. Veterinary Surgery, 43(7), 774–782. https://doi.org/10.1111/j.1532-950X.2014.12185.x

Chiti, L. E., Ferrari, R., Roccabianca, P., Boracchi, P., Godizzi, F., Busca, G. A., & Stefanello, D. (2021). Surgical margins in canine cutaneous soft-tissue sarcomas: A dichotomous classification system does not accurately predict the risk of local recurrence. Animals, 11(8), 2367. https://doi.org/10.3390/ani11082367

Dennis, M. M., McSporran, K. D., Bacon, N. J., Schulman, F. Y., Foster, R. A., & Powers, B. E. (2011). Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs. Veterinary Pathology, 48(1), 73–84. https://doi.org/10.1177/0300985810388820

Elmslie, R. E., Glawe, P., & Dow, S. W. (2008). Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. Journal of Veterinary Internal Medicine, 22(6), 1373–1379. https://doi.org/10.1111/j.1939-1676.2008.0179.x

Fonseca-Alves, C. E., Biondi, L. R., dos Anjos, D. S., de Oliveira, K. D., Batschinski, K., Lucas, S. R. R., . . . De Nardi, A. B. (2026). Canine cutaneous and subcutaneous soft tissue sarcoma in dogs: A consensus report from the Brazilian Association of Veterinary Oncology. Frontiers in Veterinary Science, 13, 1750148. https://doi.org/10.3389/fvets.2026.1750148

Hildebrandt, I. M., Skinner, O. T., Mickelson, M. A., Daniel, T. E., Ashworth, H. L., Kim, A., . . . Maitz, C. A. (2025). Surgery and postoperative definitive radiotherapy for management of canine soft tissue sarcoma: A multi-institutional retrospective study of 272 dogs (2010–2020). Journal of the American Veterinary Medical Association, 263(3). https://doi.org/10.2460/javma.24.06.0363

Liptak, J. M., & Christensen, N. I. (2020). Soft tissue sarcomas. In D. M. Vail, D. H. Thamm, & J. M. Liptak (Eds.), Withrow and MacEwen's small animal clinical oncology (6th ed., pp. 404–431). Elsevier. https://doi.org/10.1016/B978-0-323-59496-7.00022-0

Perry, J. A., Culp, W. T. N., Dailey, D. D., Eickhoff, J. C., Kamstock, D. A., & Thamm, D. H. (2014). Diagnostic accuracy of pre-treatment biopsy for grading soft tissue sarcomas in dogs. Veterinary and Comparative Oncology, 12(2), 106–113. https://doi.org/10.1111/j.1476-5829.2012.00333.x

Last reviewed: 07/29/2026

This article is intended for educational purposes and does not replace individualized veterinary advice. Every dog's situation is different, and treatment decisions should be made in consultation with your veterinary team.